Status:
COMPLETED
Biomarker Monitoring in TP53 Mutation Carriers
Lead Sponsor:
Scripps Health
Collaborating Sponsors:
J. Craig Venter Institute
Conditions:
Li-Fraumeni Syndrome
Hereditary Cancer Syndromes
Eligibility:
All Genders
Brief Summary
Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene. An individual with this mutation...
Detailed Description
Individuals who carry certain germline TP53 gene mutations are highly susceptible to cancer and are likely to develop any one, or many, cancer types during their lifetimes. Prevention strategies and e...
Eligibility Criteria
Inclusion
- Any individual and their family with a known functionally significant germline TP53 mutation susceptible to Li-Fraumeni Syndrome.
- Any individual and their family with a known hereditary cancer syndrome.
Exclusion
- No functionally significant germline TP53 gene mutation.
- Inability to tolerate intensive biomonitoring.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02289326
Start Date
July 1 2014
End Date
July 1 2016
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Clinic Medical Group
La Jolla, California, United States, 92037